Pharming Group N.V. PHAR Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$12.29 down $0.01, 0.08% at close Nov 6
Last close · Previous close $12.30
- Market cap
- $869.86MAt the Nov 6 close
- P/E ratio
- 32.72On last 12 months’ EPS
- Diluted EPS
- $0.38Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$12.29up $2.61, 26.96%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$12.30Nov 5
- Volume9.73KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume16.52KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $9.11 to $21.34; now $12.29
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PHAR beat the S&P 500 in 2 of 6 periods.
| Period | PHAR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PHAR: up 27.0% S&P 500: down 5.6% | PHAR beat the S&P 500 by 32.6 percentage points Beat |
| 3M | PHAR: up 13.3% S&P 500: down 4.1% | PHAR beat the S&P 500 by 17.4 percentage points Beat |
| YTD | PHAR: down 30.4% S&P 500: up 8.7% | PHAR trailed the S&P 500 by 39.1 percentage points Trailed |
| 1Y | PHAR: down 16.4% S&P 500: up 10.9% | PHAR trailed the S&P 500 by 27.3 percentage points Trailed |
| Long term | ||
| 3Y | PHAR: up 0.2% S&P 500: up 75.0% +0.1% vs +20.5% a year | PHAR trailed the S&P 500 by 74.8 percentage points Trailed |
| 5Y | PHAR: up 32.2% S&P 500: up 67.8% +5.7% vs +10.9% a year | PHAR trailed the S&P 500 by 35.6 percentage points Trailed |
$10,000 invested in PHAR 5 years ago (Nov 5, 2021) would be worth about $13,215 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
PHAR beat the S&P 500 in 2 of 6 periods.
| Period | PHAR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PHAR: up 27.0% S&P 500: down 5.6% | PHAR beat the S&P 500 by 32.6 percentage points Beat |
| 3M | PHAR: up 13.3% S&P 500: down 4.3% | PHAR beat the S&P 500 by 17.6 percentage points Beat |
| YTD | PHAR: down 30.4% S&P 500: up 7.8% | PHAR trailed the S&P 500 by 38.2 percentage points Trailed |
| 1Y | PHAR: down 16.4% S&P 500: up 9.7% | PHAR trailed the S&P 500 by 26.1 percentage points Trailed |
| Long term | ||
| 3Y | PHAR: up 0.2% S&P 500: up 68.8% +0.1% vs +19.1% a year | PHAR trailed the S&P 500 by 68.6 percentage points Trailed |
| 5Y | PHAR: up 32.2% S&P 500: up 56.9% +5.7% vs +9.4% a year | PHAR trailed the S&P 500 by 24.7 percentage points Trailed |
$10,000 invested in PHAR 5 years ago (Nov 5, 2021) would be worth about $13,215 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$21.18
Closing high on . Now 42.0% below that record.
Split-adjusted daily closes since Dec 23, 2020.
Stock splits
PHAR hasn’t split since its price history begins in 2020.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Sep 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
32.7×The Nov 6 close ÷ diluted EPS over the last 12 months ($0.38)
The range covers daily P/E ratios from Oct 29, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
PHAR trades at 32.7× its earnings over the last 12 months, below its 5-year median of 44.3×. In plain terms, buyers are paying about $33 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 2.0×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 26.4×Book value as of Sep 30, 2026
Price relative to accounting equity (book value) per share on the Sep 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 14.9×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 0.01Last 12 months’ EPS growth
The P/E divided by the growth in diluted EPS over the last 12 months (+2,404.0% on the 12 months before). It looks backward: near 1 means the P/E roughly matches last year’s growth. Sites that use analysts’ growth forecasts show a different PEG.
PEG = P/E ÷ EPS growth (%) = 32.7 ÷ 2,404.0 - 4.54%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $785.83MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Sep 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own PHAR DCF in Excel. Value Pharming Group with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $445.15Mup 9.7%
- Net income
- $27.50Mup 1,827.1%
- Diluted EPS
- $0.38up 2,404.0%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $96.43M | $2.98M | $0.04 |
| Q1 FY25 (Mar 31, 2025) | $85.60M | −$15.93M | −$0.24 |
| Q2 FY25 (Jun 30, 2025) | $109.67M | $5.52M | $0.08 |
| Q3 FY25 (Sep 30, 2025) | $114.19M | $8.86M | $0.13 |
| Q4 FY25 (Dec 31, 2025) | $125.18M | $6.26M | $0.09 |
| Q1 FY26 (Mar 31, 2026) | $83.85M | −$6.03M | −$0.08 |
| Q2 FY26 (Jun 30, 2026) | $102.98M | $1.87M | $0.02 |
| Q3 FY26 (Sep 30, 2026) | $133.13M | $25.40M | $0.34 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $225.22M | $18.12M | $0.26 |
| FY22 (Dec 31, 2022) | $219.21M | $14.58M | $0.20 |
| FY23 (Dec 31, 2023) | $271.67M | −$11.68M | −$0.18 |
| FY24 (Dec 31, 2024) | $309.26M | −$12.32M | −$0.19 |
| FY25 (Dec 31, 2025) | $441.99M | $3.35M | $0.05 |
Margins
- Gross 85.1%
- Operating 8.3%
- Net 6.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $39.47MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$40.48MLast 12 months
- Capital spending$1.00MLast 12 months
- 8.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $12.73MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $225.94MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$129.69MAs of Sep 30, 2026
- Net cash$96.26MAs of Sep 30, 2026
- 3.23As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.39As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 8.6%Last 12 months
Over the last 12 months, Pharming Group’s net income was 8.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 4.9%Last 12 months
Over the last 12 months, Pharming Group’s net income was 4.9% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Pharming Group N.V.
Pharming Group N.V.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Netherlands
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PHAR news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PHAR stock FAQ
What is PHAR stock’s price today?
Pharming Group (PHAR) traded at $12.29 at the close on , down $0.01 (0.08%) from the previous close of $12.30. Over the past 52 weeks it has traded between $9.11 and $21.34.
If you invested $1,000 in PHAR 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PHAR on would be worth about $1,322 at the close on , a total return of +32.2%. The same $1,000 would be worth $836 if invested one year ago. Past performance doesn’t predict future returns.
What is Pharming Group’s market cap?
Pharming Group’s market capitalization is about $869.9 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $12.29 (how market cap works). Pharming Group reported 707.78M shares outstanding at the end of its latest quarter ().
What is PHAR’s P/E ratio?
PHAR trades at 32.7 times its diluted earnings over the four quarters to ($0.38 per share), at the close. Over the past five years its P/E has ranged from 18.8 to 420.4, with a median of 44.3. (How the P/E ratio works.)
How much revenue does Pharming Group make?
Pharming Group reported $445.2 million of revenue over the four quarters to , up 9.7% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $133.1 million, up 16.6% from a year earlier.
Is Pharming Group profitable?
Yes. Pharming Group earned $27.5 million of net income over the four quarters to , a net margin of 6.2%, and its operating margin was 8.3% (what margins tell you).
What are PHAR’s earnings per share?
PHAR’s diluted earnings per share were $0.38 over the four quarters to , compared with $0.02 in the twelve months before. The latest quarter (Q3 FY26) brought $0.34 per share, against $0.13 a year earlier (how EPS works).
Does PHAR pay a dividend?
Pharming Group hasn’t paid a dividend in the last twelve months.
What is PHAR’s 52-week high and low?
Over the past 52 weeks PHAR has traded as low as $9.11 and as high as $21.34. At $12.29 at the close on , it is 42.4% below that high and 34.9% above the low.
What is PHAR’s all-time high?
PHAR’s highest closing price was $21.18 on , adjusted for stock splits. At $12.29 at the close on , it is 42.0% below that record.
Has PHAR stock ever split?
No. PHAR hasn’t split since its price history begins in 2020.
How has PHAR stock performed?
Including dividends and measured to the close on , PHAR has returned −30.4% so far this year and −16.4% over the past year, and +32.2% over five years (+5.7% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Pharming Group in?
Pharming Group is in the Healthcare sector and the Biotechnology industry, and is headquartered in Netherlands.
What exchange does PHAR trade on?
Pharming Group trades on the Nasdaq under the ticker symbol PHAR. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.